[HTML][HTML] Strategies to improve outcomes of patients with EGFR-mutant non–small cell lung cancer: review of the literature
C Zhou, L Di Yao - Journal of Thoracic Oncology, 2016 - Elsevier
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) monotherapy has
been regarded as the standard first-line treatment of advanced non–small cell lung cancer …
been regarded as the standard first-line treatment of advanced non–small cell lung cancer …
[引用][C] Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature
C Zhou, L Di Yao - Journal of Thoracic Oncology, 2016 - cir.nii.ac.jp
Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer:
Review of the Literature | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …
Review of the Literature | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …
Strategies to Improve Outcomes of Patients with EGRF-Mutant Non-Small Cell Lung Cancer: Review of the Literature
C Zhou, L Di Yao - … of the International Association for the …, 2016 - pubmed.ncbi.nlm.nih.gov
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) monotherapy has
been regarded as the standard first-line treatment of advanced non-small cell lung cancer …
been regarded as the standard first-line treatment of advanced non-small cell lung cancer …
[PDF][PDF] Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature
C Zhou, MD Luan Di Yao - Journal of Thoracic Oncology, 2015 - core.ac.uk
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) monotherapy has
been regarded as the standard first-line treatment of advanced non–small cell lung cancer …
been regarded as the standard first-line treatment of advanced non–small cell lung cancer …
[HTML][HTML] Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature
C Zhou, L Di Yao - Journal of Thoracic Oncology, 2016 - jto.org
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) monotherapy has
been regarded as the standard first-line treatment of advanced non–small cell lung cancer …
been regarded as the standard first-line treatment of advanced non–small cell lung cancer …
Strategies to Improve Outcomes of Patients with EGRF-Mutant Non-Small Cell Lung Cancer: Review of the Literature.
C Zhou, LD Yao - Journal of Thoracic Oncology: Official Publication …, 2015 - europepmc.org
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) monotherapy has
been regarded as the standard first-line treatment of advanced non-small cell lung cancer …
been regarded as the standard first-line treatment of advanced non-small cell lung cancer …